<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350414</url>
  </required_header>
  <id_info>
    <org_study_id>10-01</org_study_id>
    <nct_id>NCT01350414</nct_id>
  </id_info>
  <brief_title>AIR2 Extension Study to Demonstrate Longer-term (&gt; 1 Year) Durability of Effectiveness</brief_title>
  <acronym>PAS1</acronym>
  <official_title>AIR2 Extension Study to Demonstrate Longer-term (&gt; 1 Year) Durability of Effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate durability of effectiveness (beyond one year) of
      the Alair System in patients with severe persistent asthma. The study will consist of
      Alair-group subjects who are currently in the follow-up phase (out to 5 years) of the AIR2
      Trial (Protocol #04-02, clinicaltrials.gov number NCT00231114).

      Durability of the treatment effect will be evaluated by comparing the proportion of subjects
      who experience severe exacerbations during the first year after Alair treatment with the
      proportion of subjects who experience severe exacerbations during subsequent 12 month periods
      out to 5 years.

      All Alair group subjects in the AIR2 Trial are being followed out to 5 years as per the AIR2
      Trial protocol. The data that are to be used to determine durability of effectiveness as
      described in the present protocol (Protocol #10-01) are being collected under the existing
      AIR2 Trial protocol (Protocol # 04-02).

      Study Hypothesis: An empirical demonstration of the durability of the treatment effect will
      be used to show that the proportion of subjects experiencing severe exacerbations for the
      first year compared with the proportions of subjects experiencing severe exacerbations in
      subsequent years do not get substantially worse.

      The primary statistical objective is to demonstrate that the proportion of subjects who
      experience severe exacerbations in the subsequent 12-month follow-up (for Year 2, Year 3,
      Year 4 and Year 5 [in 12-month periods]) is not statistically worse when compared with the
      proportion of first 12-months, which begins 6-weeks after the last Alair treatment. This
      objective will be met if the upper 95% confidence limit of the difference in proportions
      (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than
      20%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label, single arm study designed to demonstrate the durability of
      effectiveness (beyond one year) of the Alair System in patients with severe persistent
      asthma.

      Durability of treatment effect will be evaluated by comparison of the proportion of subjects
      experiencing severe exacerbations during the first year after the Alair treatment to
      subsequent 12-month periods out to 5 years.

      The 12-month periods will begin 6 weeks post-last Alair bronchoscopy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severe Exacerbations</measure>
    <time_frame>12 month periods out to 5 Years</time_frame>
    <description>The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment compared to subsequent 12-month periods out to 5 years. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%.
Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe Exacerbations</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Number of severe exacerbations per subject per year. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Adverse Events</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Number of respiratory adverse events per subject per year. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Adverse Events</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Proportion of subjects experiencing one or more respiratory adverse event in each of the years 1 through 5 following the Alair treatment. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the &quot;Respiratory System&quot; that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Room Visits for Respiratory Symptoms</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Proportion of Subjects with Emergency Room Visits for Respiratory Symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Room (ER) Visits for Respiratory Symptoms</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Number of Emergency Room Visits for Respiratory Symptoms per subject per year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations for Respiratory Symptoms</measure>
    <time_frame>12 Month periods out to 5 Years</time_frame>
    <description>Proportion of subjects with hospitalizations for respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations for Respiratory Symptoms</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Number of Hospitalizations for Respiratory Symptoms per subject per year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Pre-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>12 Month periods out to 5 years</time_frame>
    <description>Post-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">181</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Alair Group</arm_group_label>
    <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bronchial Thermoplasty with the Alair System</intervention_name>
    <description>Bronchial Thermoplasty with the Alair System</description>
    <arm_group_label>Alair Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All Alair group subjects who have participated in the AIR2 Trial (NCT00231114) and were not
        lost to follow-up at the end of the 12 month premarket visit, and those who are willing to
        comply with the study protocol and routine visits for the duration of the study will be
        included in the post-approval study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Alair group subjects who have participated in the AIR2 Trial (NCT00231114) and
             were not lost to follow-up at the end of the 12 month premarket visit, and those who
             are willing to comply with the study protocol and routine visits for the duration of
             the study will be included in the post-approval study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narinder S Shargill, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Asthmatx, Inc.</affiliation>
  </overall_official>
  <reference>
    <citation>Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24. doi: 10.1164/rccm.200903-0354OC. Epub 2009 Oct 8.</citation>
    <PMID>19815809</PMID>
  </reference>
  <results_reference>
    <citation>Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Hales JB, McEvoy C, Slebos DJ, Holmes M, Phillips MJ, Erzurum SC, Hanania NA, Sumino K, Kraft M, Cox G, Sterman DH, Hogarth K, Kline JN, Mansur AH, Louie BE, Leeds WM, Barbers RG, Austin JH, Shargill NS, Quiring J, Armstrong B, Castro M; Asthma Intervention Research 2 Trial Study Group. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec;132(6):1295-302. doi: 10.1016/j.jaci.2013.08.009. Epub 2013 Aug 30.</citation>
    <PMID>23998657</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <results_first_submitted>June 17, 2015</results_first_submitted>
  <results_first_submitted_qc>August 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2016</results_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alair Group</title>
          <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02)
Bronchial Thermoplasty with the Alair System: Bronchial Thermoplasty with the Alair System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 2</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 3</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 4</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year 5</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>AIR2 Extension Subjects Completing Follow-up at Year 1</population>
      <group_list>
        <group group_id="B1">
          <title>Alair Group</title>
          <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.8" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.9" spread="17.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ICS Dose (Inhaled Corticosteroid dose)</title>
          <units>mcg/day (micrograms/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1943.9" spread="722.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LABA Dose (Long-acting Beta Agonists)</title>
          <units>mcg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.2" spread="45.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OCS Dose (Oral corticosteroids)</title>
          <description>This measure includes only 7 participants using OCS at baseline.</description>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ) Score</title>
          <description>There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.32" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Bronchodilator FEV1 (Forced Expiratory Volume in 1 second)</title>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.8" spread="15.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post-Bronchodilator FEV1 (Forced Expiratory Volume in 1 second)</title>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>amPEF (Peak Expiratory Flow)</title>
          <units>L/min (liters per minute)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="383.4" spread="104.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severe Exacerbations</title>
        <description>The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment compared to subsequent 12-month periods out to 5 years. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%.
Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).</description>
        <time_frame>12 month periods out to 5 Years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Exacerbations</title>
          <description>The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment compared to subsequent 12-month periods out to 5 years. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%.
Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Percentage subjects severe exacerbations</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="24.2" upper_limit="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" lower_limit="17.2" upper_limit="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="26.7" upper_limit="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" lower_limit="29" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="15.3" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Exacerbations</title>
        <description>Number of severe exacerbations per subject per year. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Exacerbations</title>
          <description>Number of severe exacerbations per subject per year. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Number of events/Number of subjects/Year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.486" lower_limit="0.385" upper_limit="0.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.406" lower_limit="0.311" upper_limit="0.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.549" lower_limit="0.435" upper_limit="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.560" lower_limit="0.444" upper_limit="0.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.309" lower_limit="0.226" upper_limit="0.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Adverse Events</title>
        <description>Number of respiratory adverse events per subject per year. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the “Respiratory System” that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Adverse Events</title>
          <description>Number of respiratory adverse events per subject per year. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the “Respiratory System” that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Number of events/number of subject/Year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.022" lower_limit="1.764" upper_limit="2.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.218" lower_limit="1.013" upper_limit="1.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.247" lower_limit="1.037" upper_limit="1.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.176" lower_limit="0.971" upper_limit="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.778" lower_limit="0.616" upper_limit="0.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Adverse Events</title>
        <description>Proportion of subjects experiencing one or more respiratory adverse event in each of the years 1 through 5 following the Alair treatment. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the “Respiratory System” that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Adverse Events</title>
          <description>Proportion of subjects experiencing one or more respiratory adverse event in each of the years 1 through 5 following the Alair treatment. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the “Respiratory System” that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Percentage subjects with respiratory AE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="66.5" upper_limit="79.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="51.3" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="50.4" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" lower_limit="47" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="39.8" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Room Visits for Respiratory Symptoms</title>
        <description>Proportion of Subjects with Emergency Room Visits for Respiratory Symptoms</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Room Visits for Respiratory Symptoms</title>
          <description>Proportion of Subjects with Emergency Room Visits for Respiratory Symptoms</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Percentage subjects ER respir. symptoms</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1.8" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="2.9" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3.8" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="3" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="2" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Room (ER) Visits for Respiratory Symptoms</title>
        <description>Number of Emergency Room Visits for Respiratory Symptoms per subject per year.</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Room (ER) Visits for Respiratory Symptoms</title>
          <description>Number of Emergency Room Visits for Respiratory Symptoms per subject per year.</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Number of events/subject/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.072" lower_limit="0.048" upper_limit="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.085" lower_limit="0.058" upper_limit="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.136" lower_limit="0.100" upper_limit="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.094" lower_limit="0.065" upper_limit="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" lower_limit="0.044" upper_limit="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalizations for Respiratory Symptoms</title>
        <description>Proportion of subjects with hospitalizations for respiratory symptoms.</description>
        <time_frame>12 Month periods out to 5 Years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations for Respiratory Symptoms</title>
          <description>Proportion of subjects with hospitalizations for respiratory symptoms.</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Percentage of subjects hospitalized</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.7" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="1.2" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="2.5" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="2.1" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalizations for Respiratory Symptoms</title>
        <description>Number of Hospitalizations for Respiratory Symptoms per subject per year.</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations for Respiratory Symptoms</title>
          <description>Number of Hospitalizations for Respiratory Symptoms per subject per year.</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Number of events/subjects/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" lower_limit="0.025" upper_limit="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" lower_limit="0.042" upper_limit="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" lower_limit="0.048" upper_limit="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" lower_limit="0.054" upper_limit="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.014" upper_limit="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Pre-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Pre-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Percentage of change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="14.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="15.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="15.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="14.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Post-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.</description>
        <time_frame>12 Month periods out to 5 years</time_frame>
        <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Alair Group</title>
            <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol Number 04-02, NCT00231114).</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Post-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.</description>
          <population>Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.</population>
          <units>Percentage of change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months out to 5 years</time_frame>
      <desc>In previous outcome analysis and in the participant flow, the denominator was based on the number of subjects that completed the corresponding annual visit. For Adverse Events the denominator was based on all the subjects that entered that period regardless of whether they completed the annual visit or not for that period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Year 1</title>
          <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).
Year 1 is defined as 365 days from the treatment period (6 weeks after the last bronchoscopy). All subjects were considered in the analysis regardless of whether they have completed the Year 1 annual visit or not.</description>
        </group>
        <group group_id="E2">
          <title>Year 2</title>
          <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).
Year 2 is defined as 366 to 730 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 2 annual visit or not.</description>
        </group>
        <group group_id="E3">
          <title>Year 3</title>
          <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).
Year 3 is defined as 731 to 1095 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 3 annual visit or not.</description>
        </group>
        <group group_id="E4">
          <title>Year 4</title>
          <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).
Year 4 is defined as 1096 to 1460 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 4 annual visit or not.</description>
        </group>
        <group group_id="E5">
          <title>Year 5</title>
          <description>Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).
Year 5 is defined as 1461 days to 1826 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 5 annual visit or not.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Infective tenosynovitis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Viral labyrinthitis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <description>Non-respiratory</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="163"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="163"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="87" subjects_affected="52" subjects_at_risk="187"/>
                <counts group_id="E2" events="77" subjects_affected="47" subjects_at_risk="168"/>
                <counts group_id="E3" events="82" subjects_affected="48" subjects_at_risk="163"/>
                <counts group_id="E4" events="81" subjects_affected="51" subjects_at_risk="163"/>
                <counts group_id="E5" events="52" subjects_affected="40" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="187"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="163"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="187"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="168"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="81" subjects_affected="57" subjects_at_risk="187"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="168"/>
                <counts group_id="E3" events="25" subjects_affected="24" subjects_at_risk="163"/>
                <counts group_id="E4" events="28" subjects_affected="23" subjects_at_risk="163"/>
                <counts group_id="E5" events="23" subjects_affected="18" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <description>Respiratory</description>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Narinder Shargill</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>408-635-3907</phone>
      <email>Narinder.Shargill@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

